The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


Drug Intelligence & Clinical Pharmacy: Vol. 22, No. 2, pp. 99-106.
© 1988 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Longnecker, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Longnecker, S.


Research Articles

Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia

SM Longnecker

The somatostatins represent endogenous substances that serve a diversity of functions in the body. These activities are just beginning to be understood and could have major implications in the treatment of human disease. Their chief pharmacologic activities lie in the modification or modulation of protein hormone synthesis of the gastrointestinal system; a great many other systems may be involved as well. Since the discovery of the therapeutic potentials of naturally isolated somatostatins, attempts have been made to design newer analogs more conducive to practical use. Such an example is long-acting somatostatin analog octreotide. Literature has recently begun to appear describing the therapeutic activities of this and other similar compounds and the first steps to understanding their clinical pharmacology are being taken. Surprising activity has been found in the palliative treatment of a wide variety of formerly resistant gastrointestinal syndromes and endocrine tumors. These activities may have considerable future impact on the treatment of disease involving hormonal imbalance or inappropriate secretion.


This article has been cited by other articles:


Home page
Ann OncolHome page
M. Hejna, M. Schmidinger, and M. Raderer
The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?
Ann. Onc., May 1, 2002; 13(5): 653 - 668.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1988 by Harvey Whitney Books Company.